Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
NCT01758458Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2013
- Primary completion
- May 2016
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of MCPyV TAg-specific polyclonal autologous CD8-positive T cells in Merkel cell carcinoma (MCC), sponsored by Fred Hutchinson Cancer Center. Started Feb 2013; status: terminated.
02
Drugs
MCPyV TAg-specific polyclonal autologous CD8-positive T cells
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT01758458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01758458.